Canadian Firms Partner On Cannabinoid-Based Therapies For Mood Disorders
This article was originally published in The Pink Sheet Daily
Executive Summary
Anxiety and depression are on the list of disorders targeted by Cannasat/IntelGenx collaboration to develop cannabinoid-based CAT 320.
You may also be interested in...
CeNeRx Biopharma Licenses Cannabinoid Compounds To Study For CNS Indications
First clinical candidate anticipated in “a year or two,” company tells “The Pink Sheet” DAILY.
CeNeRx Biopharma Licenses Cannabinoid Compounds To Study For CNS Indications
First clinical candidate anticipated in “a year or two,” company tells “The Pink Sheet” DAILY.
GW Licenses U.S. Sativex Rights To Otsuka In $273 Million Deal
Firms plan to enter a longer-term collaboration later this year to discover novel cannabinoids for use in pain and central nervous system disorders.